IP Library › Assignment 024300/0825
Patent Assignment
Reel/Frame 024300/0825

Security Agreement (Patents)

Recorded: 2010-04-28 Received: 2010-04-28 Pages: 16
Assignor
Assignee
CEQUENT PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, BUILDING 700, CAMBRIDGE, MA, 02139, UNITED STATES
Covered Properties (53)
Intranasal Carbetocin Formulations and Methods for the Treatment of Autism
Application: 12/599,267 →
Gras Composition for Intranasal Delivery of Parathyroid Hormone
Application: 12/726,315 →
Intranasal Administration of Rapid Acting Insulin
Application: 12/672,478 →
Phage Displayed Cell Binding Peptides
Application: 12/701,397 →
Usirna Complexes
Compositions and Methods for Triggered Release Rna Therapeutics
Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
Nucleic Acid Compounds for Inhibiting Gene Expression and Uses Thereof
Application: 12/552,082 →
Nucleic Acid Compounds for Inhibiting BIRC5 Gene Expression and Uses Thereof
Nucleic Acid Compounds for Inhibiting PLK1 Gene Expression and Uses Thereof
Ribonucleic Acids with Non-Standard Bases and Uses Thereof
Application: 12/486,889 →
Multi-Arm Amines and Uses Thereof
Hydroxymethyl Substituted Rna Oligonucleotides and Rna Complexes
Application: 12/515,403 →
Nicked or Gapped Nucleic Acid Molecules and Uses Thereof
Application: 12/445,868 →
Compounds and Methods for Peptide Ribonucleic Acid Condensate Particles for Rna Therapeutics
Application: 12/445,575 →
Compositions and Methods for Efficient Delivery of Gene Silencing Therapeutics
Application: 61/167,379 →
Compositions for Intranasal Delivery of Human Insulin and Uses Thereof
Application: 12/376,205 →
Lipopeptides for Delivery of Nucleic Acids
Compositions for Enhanced Epithelial Permeation of Neuropeptide Y for Treating Obesity
Application: 12/234,547 →
Compositions and Methods for Enhancing Delivery of Nucleic Acids into Cells and for Modifying Expression of Target Genes in Cells
Application: 12/206,165 →
Modification of Double-Stranded Ribonucleic Acid Molecules
Application: 12/065,604 →
Uses of Broad Spectrum Rnai Therapeutics Against Influenza
Application: 12/189,563 →
Amino Acid Lipids and Uses Thereof
Application: 12/114,284 →
Tight Junction Modulating Peptide Components for Enhancing Mucosal Delivery of Therapeutic Agents
Application: 11/997,132 →
Methods and Compositions for Enhancing Delivery of Double-Stranded Rna or a Double-Stranded Hybrid Nucleic Acid to Regulate Gene Expression in Mammalian Cells
Application: 12/013,274 →
Phage Displayed Trp Cage Ligands
Application: 11/955,207 →
Rnai Therapeutic for Respiratory Virus Infection
Application: 11/910,971 →
Device for Improved Peptide Delivery
Application: 11/774,492 →
FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
Application: 11/750,979 →
Compositions and Methods for Enhanced Mucosal Delivery of Parathyroid Hormone
Application: 11/744,745 →
COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
Application: 11/743,480 →
Method of Treating an Inflammatory Disease by Double Stranded Ribonucleic Acid
Application: 11/576,139 →
Rnai Therapeutic for Respiratory Virus Infection
Application: 11/687,564 →
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
Application: 11/676,221 →
Compositions and Methods for Complexes of Nucleic Acids and Organic Cations
Application: 11/676,226 →
Phage Displayed Cell Binding Peptides
Application: 11/627,863 →
Method for Opening Tight Junctions
Application: 11/624,630 →
Dry Powder Compositions for Rna Influenza Therapeutics
Application: 11/623,306 →
COMPOSITIONS AND METHODS EMPLOYING UNIVERSAL-BINDING NUCLEOTIDES FOR TARGETING MULTIPLE GENE VARIANTS WITH A SINGLE siRNA DUPLEX
Application: 11/610,403 →
Compositions and Methods for Enhanced Mucosal Delivery of Parathyroid Hormone
Application: 11/550,051 →
Compositions and Methods for the Treatment of Psychiatric Disorders
Application: 11/537,468 →
Pharmaceutical compositions for delivery of ribonucleic acid to a cell
Application: 11/223,699 →
Double-stranded ribonucleic acid molecules having ribothymidine
Application: 11/219,625 →
Compositions and Methods for Enhanced Mucosal Delivery of Parathyroid Hormone
Application: 11/126,996 →
Phage Displayed Trp Cage Ligands
Application: 10/976,942 →
Compositions and Methods for Enhanced Mucosal Delivery and Non-Infused Administration of Y2 Receptor-Binding Peptides and Methods for Treating and Preventing Obesity
Application: 10/869,649 →
Compositions and Methods for Enhanced Mucosal Delivery of Y2 Receptor-Binding Peptides and Methods for Treating and Preventing Obesity
Application: 10/780,325 →
Compositions and Methods for Enhanced Mucosal Delivery of Y2 Receptor-Binding Peptides and Methods for Treating and Preventing Obesity
Application: 10/768,288 →
Compositions and Methods for Enhanced Mucosal Delivery of Y2 Receptor-Binding Peptides and Methods for Treating and Preventing Obesity
Application: 10/745,069 →
Pyrido[2,3-D]Pyrimidine and Pyrimido[4,5-D]Pyrimidine Nucleosides
Application: 10/221,397 →
Compositions and Methods for Enhanced Mucosal Delivery of Peptide Yy and Methods for Treating and Preventing Obesity
Application: 10/322,266 →
Novel Nucleosides Having Bicyclic Sugar Moiety
Application: 10/136,932 →
Pyrrolo[2,3-D]Pyrimidine Nucleoside Analogs
Application: 09/797,549 →